<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162769</url>
  </required_header>
  <id_info>
    <org_study_id>APD334-201</org_study_id>
    <nct_id>NCT04162769</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis</brief_title>
  <acronym>ADVISE</acronym>
  <official_title>A Multicenter, Randomized, Double-Blinded, Placebo-Controlled 16-Week Study (With a 52-Week Open-Label Extension) to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether etrasimod is a safe and effective treatment
      for moderate to severe atopic dermatitis (AD).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving EASI-75</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>EASI-75, defined as a 75% reduction of EASI from Baseline to Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With a Validated Investigator's Global Assessment (vIGA) 0 to 1 (on a 5-point Scale) Score and a Reduction From Baseline of ≥ 2 Points</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in EASI</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in vIGA Score</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>12-Week Double-Blind Treatment Period: Etrasimod Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>12-Week Double-Blind Treatment Period: Etrasimod Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>12-Week Double-Blind Treatment Period: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>52-Week Open-Label Extension Period: Etrasimod Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etrasimod</intervention_name>
    <description>Etrasimod &quot;Dose A&quot; tablet taken by mouth, once daily up to 12 weeks during the Double-Blind Treatment Period</description>
    <arm_group_label>12-Week Double-Blind Treatment Period: Etrasimod Dose A</arm_group_label>
    <other_name>APD334</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etrasimod</intervention_name>
    <description>Etrasimod &quot;Dose B&quot; tablet taken by mouth, once daily up to 12 weeks during the Double-Blind Treatment Period</description>
    <arm_group_label>12-Week Double-Blind Treatment Period: Etrasimod Dose B</arm_group_label>
    <other_name>APD334</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etrasimod matching placebo</intervention_name>
    <description>Etrasimod matching placebo tablet by mouth, once daily up to 12 weeks during the Double-Blind Treatment Period</description>
    <arm_group_label>12-Week Double-Blind Treatment Period: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etrasimod</intervention_name>
    <description>Etrasimod &quot;Dose B&quot; tablet taken by mouth, once daily up to 52 weeks during the Open-Label Extension Period</description>
    <arm_group_label>52-Week Open-Label Extension Period: Etrasimod Dose B</arm_group_label>
    <other_name>APD334</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Participants with chronic atopic dermatitis, defined by Hanifin and Rajka criteria,
             that has been present for at least 1 year prior to the Screening Visit

          -  Participants with Eczema Area and Severity Index (EASI) ≥ 12 at the Screening Visit
             and ≥ 16 at the Baseline Visit

          -  Participants with validated Investigator's Global Assessment (vIGA) score ≥ 3 (on the
             0 to 4 vIGA scale, in which 3 = moderate and 4 = severe) involvement at the Screening
             and Baseline visits

        Exclusion Criteria:

          -  Presence of skin comorbidities that would interfere with study assessments of the
             underlying disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arena CT.gov Administrator</last_name>
    <role>Study Director</role>
    <affiliation>Arena Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Noble Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prohealth Research Center</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aby's New Generation Research, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Miami Medical &amp; Research Group. Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Research of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research Inc</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29369</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modern Research Associates, PLLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research, LLC</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate-to-severe atopic dermatitis</keyword>
  <keyword>Etrasimod</keyword>
  <keyword>APD334</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

